Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster presented at the ISPOR 2025; May 14, 2025. Montréal, Canada.
Toplak H, Bilitou A, Alber H, Auer J, Clodi M, Ebenbichler C, FlieBer-Gorzer E, Gelsinger C, Hanusch U, Ludvik B, Maca T, Schober A, Sock R, Speidl WS, Stulnig TM, Weitgasser R, Zirlik A, Koch M, Wienerroither S, Wolowacz SE, Diamand F, Catapano AL. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients. Wein Klin Wochenschr. 2023 Jul;135(13-14):364-74. doi: 10.1007/s00508-023-02221-4
Hawe E, Meleth S, Wolowacz S, Bilitou A. Importance of baseline LDL-C in the association between LDL-C lowering and cardiovascular risk: a meta-regression analysis. Poster presented at the 90th EAS Congress; May 22, 2022. Milan, Italy. [abstract] Atherosclerosis. 2022 Aug; 355:184-5. doi: 10.1016/j.atherosclerosis.2022.06.760
Layton JB, Forns J, Turner ME, Dempsey C, Bartsch JL, Anthony MS, Danysh HE, Ritchey ME, Demos G. Falls and fractures in patients with Parkinson's Disease–related psychosis treated with Pimavanserin vs atypical antipsychotics: a cohort study. Drugs Real World Outcomes. 2022 Mar;9(1):9-22. doi: 10.1007/s40801-021-00284-1
Jia X, Zhao Y, Carrico J, Brodtkorb T-H, Mendelsohn AM, Lowry S, Feldman S, Wu JJ, Armstrong AW. Cost-effectiveness of tildrakizumab for the treatment of moderate-to-severe psoriasis in the United States. J Dermatolog Trea. 2022 Mar;33(2):740-8. doi: 10.1080/09546634.2020.1773382
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. PLoS One. 2021 Jan 27. doi: 10.1371/journal.pone.0246121
Forns J, Layton JB, Bartsch J, Turner ME, Dempsey C, Anthony M, Ritchey ME, Demos G. Increased risk of falls and fractures in patients with psychosis and Parkinson disease. Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Nance R, Vannappagari V, Johannes C, Calingaert B, Saltus C, Boswell S, Rodriguez B, Moore R, Eron J, Geng E, Mathews WC, Saag MS, Kitahata M, Delaney JAC, Crane HM, Centers For AIDS Research Network of Integrated Clinical Systems (CNICS). Viral failure among persons living with HIV initiating dolutegravir-based vs. other recommended regimens in real-world clinical care settings. Poster presented at the IDWeek 2017 Conference; October 2017. San Diego, CA. [abstract] Open Forum Infect Dis. 2017 Oct 4; 4((Suppl 1)):S39. doi: 10.1093/ofid/ofx162.095
Purser MF, Mladsi DM, Wolowacz SE. A review of NICE technology appraisals using single-arm trials. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014. Montreal, Canada.
Gnanasakthy A, DeMuro C, Mordin M, Copley-Merriman K, Mauskopf J. The role of the patient voice in health technology assessment. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 2010. Atlanta, GA. [abstract] Value Health. 2010 May; 13(3):A19. doi: 10.1016/S1098-3015(10)72074-X
Pattanayak SK, Poulos C, Yang JC, Patil SR, Wendland KJ. Of taps and toilets: quasi-experimental protocol for evaluating community-demand-driven projects. J Water Health. 2009 Sep 1;7(3):434-51.
Lewis SA. A practical walkthrough of an epro design kickoff. Benefits and challenges with epro: outcomes and endpoints as we emerge from the long age of paper methods. Presented at the Drug Information Association conference workshop; 2005.